TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02297204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Laser Treatment
Description: All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept 2.0 mg
Description: If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
Study: NCT02439866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelatinous capsules filled with sugar as placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous methylprednisolone
Description: Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normobaric oxygen with face mask
Description: normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
Study: NCT03784105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine Phosphate
Description: 30 mL of codeine phosphate 10mg/5mL
Study: NCT00722735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin
Description: Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
Study: NCT00002494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT03784105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Siripus simplex
Description: Sugar syrup
Study: NCT04873206

Intervention type: OTHER
Intervention: routine stain by H&E.
Description: formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.

Intervention type: OTHER
Intervention: routine stain by H&E.
Description: formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.

Intervention type: OTHER
Intervention: routine stain by H&E.
Description: formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
Study: NCT02424474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic NIPT
Description: Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regular serum screening
Study: NCT00223756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Vision Intervention - Outpatient Training Program
Description: Patients receive LV therapy as outpatients
Study: NCT03018067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX227675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX227675
Study: NCT00002494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT03018067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX227675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01484743

Intervention type: PROCEDURE
Intervention: differences in surgical techniques
Description: follow the risk for morbidity after incisional hernia repair
Study: NCT04792762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP(1-30)NH2
Description: Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP(1-42)
Description: Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous administration of saline during a stepwise glucose clamp
Study: NCT00576446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell Vaccine
Description: Patients will receive three vaccines every two weeks
Study: NCT02558530

Intervention type: OTHER
Group type: OTHER
Intervention: Low carbohydrate diet
Description: Isocaloric, carbohydrate restricted diet 14 days
Study: NCT01038297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXC 001
Description: Intradermal injections of EXC 001 and placebo given on various schedules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injections of EXC 001 and placebo given on various schedules.
Study: NCT03857269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupoint Massage
Description: The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lavender essential oil
Description: Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupoint Massage and lavender essential oil
Description: At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
Study: NCT00933647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yerba Mate Tea
Description: Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea
Description: Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
Study: NCT04015583

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exergaming group
Description: Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
Study: NCT04209114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT00933647

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Apple tea
Description: Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
Study: NCT04079465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
Study: NCT03267901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food
Description: 45 g of walnut / iso-caloric white bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food
Description: 45 g of walnut / iso-caloric white bread
Study: NCT00993421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY377604
Description: Given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY377604
Description: Given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY377604
Description: Given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY377604
Description: Given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY377604
Description: Given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sibutramine
Description: given daily, orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LY377604
Description: given daily, orally for 24 weeks
Study: NCT04435184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Crizanlizumab 5.0 mg/kg in 100 ml IV once.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline 100 ml IV once.
Study: NCT03316547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SENSE Program
Description: Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
Study: NCT01179711

Intervention type: DEVICE
Group type: OTHER
Intervention: Glasses prescription
Description: At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
Study: NCT04800679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: receive 4 monthly IVB injections and then rescue IVB
Description: IVB group that receive 4 monthly IVB injections and then rescue IVB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP group
Description: PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVB injections and a modified laser
Description: Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
Study: NCT00562523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
Study: NCT02620436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Mother Shelter Model
Description: 1. Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~2. Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~3. Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility.
Study: NCT00143247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exubera® (inhaled insulin)
Description: Treatment of type 1 and type 2 diabetes with short-acting insulin
Study: NCT04209114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Description: Surgical removal of the bladder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Description: Surgical removal of the bladder

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical cystectomy (RC)
Description: Surgical removal of the bladder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Specified dose on specified days
Study: NCT01919788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Insuman Rapid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Insuman Rapid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT04117802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maple syrup
Description: Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
Study: NCT03048552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family CONNECT
Description: Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
Study: NCT02865460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
Study: NCT02129478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg).
Study: NCT02526082

Intervention type: OTHER
Intervention: Intervention
Description: Multifactorial intervention with lifestyle changes and drugs as needed
Study: NCT01480973

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
Study: NCT02088502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Description: All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Description: All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Description: All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
Study: NCT01298102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
Description: intramuscular injection of 1 dose vaccine
Study: NCT01053013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENCA macrobeads
Study: NCT01073540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin suspension (Optocef, BAYO5448)
Description: Single dose of 500 mg / 10 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin suspension (Keflex)
Description: Single dose of 500 mg / 20 mL
Study: NCT03225768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Training
Description: Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
Study: NCT04214483

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study: NCT01823783

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle biopsy
Description: Muscle biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle biopsy
Description: Muscle biopsy
Study: NCT02546440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
Study: NCT00497328

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Bicarbonate

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Bicarbonate
Study: NCT03351686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
Study: NCT04509245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone
Description: During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
Study: NCT01479595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBX258
Description: QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
Study: NCT02255565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Dose Quillivant XR
Description: Oral suspension dose once a day increasing to a 10mg dose